Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pilot, open label, multicenter, randomized clinical trial on lopinavir/ritonavir-monotherapy vs lopinavir/ritonavir plus selected nucs [nucleosides], in HIV/HCV [hepatitis C virus] coinfected patients with chronic hepatitis C or compensated cirrhosis, starting treatment with ribavirin and pegylated interferon

Next Previous
X
Search
Trial Profile

A pilot, open label, multicenter, randomized clinical trial on lopinavir/ritonavir-monotherapy vs lopinavir/ritonavir plus selected nucs [nucleosides], in HIV/HCV [hepatitis C virus] coinfected patients with chronic hepatitis C or compensated cirrhosis, starting treatment with ribavirin and pegylated interferon

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Nucleosides; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C; HIV infections
  • Focus Adverse reactions

    • Most Recent Events

    • 07 Jun 2008 The expected completion date for this trial is now 1 Dec 2010, as reported by ClinicalTrials.gov.
    • 23 Mar 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top